Search

Your search keyword '"Wilfred Marissen"' showing total 4 results
Start Over Author "Wilfred Marissen"
4 results on '"Wilfred Marissen"'

1. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Author

Cecile Geuijen, Paul Tacken, Liang-Chuan Wang, Rinse Klooster, Pieter Fokko van Loo, Jing Zhou, Arpita Mondal, Yao-bin Liu, Arjen Kramer, Thomas Condamine, Alla Volgina, Linda J. A. Hendriks, Hans van der Maaden, Eric Rovers, Steef Engels, Floris Fransen, Renate den Blanken-Smit, Vanessa Zondag-van der Zande, Abdul Basmeleh, Willem Bartelink, Ashwini Kulkarni, Wilfred Marissen, Cheng-Yen Huang, Leslie Hall, Shane Harvey, Soyeon Kim, Marina Martinez, Shaun O’Brien, Edmund Moon, Steven Albelda, Chrysi Kanellopoulou, Shaun Stewart, Horacio Nastri, Alexander B. H. Bakker, Peggy Scherle, Ton Logtenberg, Gregory Hollis, John de Kruif, Reid Huber, Patrick A. Mayes, and Mark Throsby

Subjects
Science
Abstract

The anti-tumour effect of immune checkpoint inhibitors is potentiated by CD137 agonists in preclinical models, but translation of these results to the clinical practice is hampered by toxicity. Authors describe here a human CD137xPD-L1 bispecific antibody with improved anti-cancer activity whilst maintaining low toxicity in non-human primates.

Published
2021
Full Text
View/download PDF

3. 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells

Author

Jing Zhou, Mark Throsby, Lex Bakker, Arpita Mondal, Wilfred Marissen, Paul Tacken, Steef Engels, Liang-Chuan Wang, Patrick Mayes, Cecile Geuijen, Rinse Klooster, Pieter Fokko Van Loo, Yao-Bin Liu, Arjen Kramer, Thomas Condamine, Alla Volgina, Linda Hendriks, Hans van der Maaden, Eric Rovers, Floris Fransen, Renate den Blanken-Smit, Vanessa Zondag-van der Zande, Abdul Basmeleh, Willem Bartelink, Ashwini Kulkarni, Cheng-Yen Huang, Leslie Hall, Shane Harvey, Chrysi Kanellopoulou, Shaun Stewart, Horacio Nastri, Ton Logtenberg, and Simon Plyte

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

4. Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV

Author

Barbara Petronella Sanders, Isabel de los Rios Oakes, Jeronimo Cello, Ying Liu, Eckard Wimmer, Wilfred Marissen, Philip D. Minor, Vladimir van Hoek, Jerome Custers, Andrew Macadam, Diana Edo-Matas, and Hanneke Schuitemaker

Subjects
Virus Cultivation, viruses, Cell Culture Techniques, Enzyme-Linked Immunosorbent Assay, Biology, Antibodies, Viral, Vaccines, Attenuated, medicine.disease_cause, complex mixtures, Culture Media, Serum-Free, Cell Line, Microbiology, Immunology and Microbiology(all), Chlorocebus aethiops, medicine, Animals, Vero Cells, General Veterinary, General Immunology and Microbiology, Poliovirus, Public Health, Environmental and Occupational Health, Viral Load, Virology, veterinary(all), Poliovirus Vaccine, Inactivated, Titer, Infectious Diseases, Cell culture, Polyclonal antibodies, Poliovirus Vaccine, Oral, Monoclonal, Vero cell, biology.protein, Molecular Medicine, Rabbits, Antibody, Viral load, Poliomyelitis
Abstract

Background As poliovirus eradication draws closer, alternative Inactivated Poliovirus Vaccines (IPV) are needed to overcome the risks associated with continued use of the Oral Poliovirus Vaccine and of neurovirulent strains used during manufacture of conventional (c) IPV. We have previously demonstrated the susceptibility of the PER.C6 ® cell line to cIPV strains; here we investigated the suspension cell culture platform for growth of attenuated poliovirus strains. Methods We examined attenuated Sabin strain productivity on the PER.C6 ® cell platform compared to the conventional Vero cell platform. The suitability of the suspension cell platform for propagation of rationally-attenuated poliovirus strains (stabilized Sabin type 3 S19 derivatives and genetically attenuated and stabilized MonoCre(X) strains), was also assessed. Yields were quantified by infectious titer determination and D-antigen ELISA using either serotype-specific polyclonal rabbit sera for Sabin strains or monoclonal cIPV-strain-specific antibodies for cIPV, S19 and MonoCre(X) strains. Results PER.C6 ® cells supported the replication of Sabin strains to yields of infectious titers that were in the range of cIPV strains at 32.5 °C. Sabin strains achieved 30-fold higher yields ( p ® cell platform as compared to the Vero cell platform in infectious titer and D-antigen content. Furthermore, Sabin strain productivity on the PER.C6 ® cell platform was maintained at 10 l scale. Yields of infectious titers of S19 and MonoCre(X) strains were 0.5–1 log 10 lower than seen for cIPV strains, whereas D-antigen yield and productivities in doses/ml using rationally-attenuated strains were in line with yields reported for cIPV strains. Conclusions Sabin and rationally-attenuated polioviruses can be grown to high infectious titers and D-antigen yields. Sabin strain infection shows increased productivity on the PER.C6 ® cell platform as compared to the conventional Vero cell platform. Novel cell platforms with the potential for higher yields could contribute to increased affordability of a next generation of IPV vaccines needed for achieving and maintaining poliovirus eradication.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results